EUVIMEDEUVIMED entdecken
Leserbrief

An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation

Kohei Fukuoka iD, Atsuko Nakazawa, Junko Hirato, Sumihito Nobusawa, Toshikazu Itabashi, Yuki Arakawa, Makiko Mori, Yuko Matsushita, Satoko Honda, Yutaka Tanami, Koichi Ichimura, Jun Kurihara und 1 weitere

Journal of Neuropathology & Experimental Neurology · 2023

DOI: 10.1093/jnen/nlad033 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2023. Verfasst von Kohei Fukuoka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Ganglioneuroblastoma, Rhabdoid Tumor, Central Nervous System Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, Gold Ribbons Network of Japan, Saitama Children’s Medical Center, Children’s Cancer Association in Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: The classification of embryonal tumors of the central nervous system (CNS) has greatly changed in recent years. For instance, tumor entities previously denoted as “CNS-primitive neuroectodermal tumors (PNETs)” disappeared from the revised fourth version of the World Health Organization (WHO) classification of tumors of the CNS edited in 2016 owing to extensive molecular analysis data showing clinical, pathological, and molecular heterogeneity among CNS-PNETs (1). In the most updated version of the WHO classification from 2021, embryonal tumors were subdivided into a number of new tumor entities based on the presence of genetic alterations or specific DNA methylation profiles (2). CNS ganglioneuroblastoma is a rare tumor entity that was considered a valid tumor type until the latest revision of its pathological classification (1). There are very few case reports on this tumor type and most are descriptive articles detailing their clinical or pathological appearances without the use of molecular genomic or epigenetic analyses (3). The exception is the article by Ito et al (3) that describes an MYO5A-NTRK3 fusion-positive pediatric case. Here, we describe a case of an infantile brain tumor with pathological features of CNS ganglioneuroblastoma along with SMARCA4 mutations and the methylation profile of atypical teratoid/rhabdoid tumors (AT/RT). Our case demonstrates the clinical, pathological, and molecular heterogeneity of CNS embryonal tumors and the diagnostic importance of genetic and epigenetic molecular approaches in CNS tumors. Pathological diagnoses were performed according to the revised fourth edition WHO classification of tumors of the CNS (1). All available surgical materials were examined by routine hematoxylin and eosin (H&E) staining and immunohistochemical staining for selected proteins using standard automated immunoperoxidase detection (BenchMark XT, Roche Diagnostics, Basel, Switzerland) on 5-µm sections of formalin-fixed paraffin-embedded samples. We performed comprehensive methylation analysis using the Illumina Infinium HumanMethylationEPIC BeadChip array (Illumina, San Diego, CA), which includes 866 238 CpG sites for analysis. The methods for methylation data analysis and t-distributed stochastic neighbor embedding (t-SNE) have been described previously (4). Reference methylation data of 288 CNS tumors (GSE90496) (5) and 14 SMARCA4-mutated AT/RT cases (GSE161692) (6) were obtained from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/) for comparison with our data. Mutation analysis was performed using Oncomine Tumor Mutation Load Assay (Thermo Fisher Scientific, Waltham, MA). PCR and Sanger sequencing were performed to validate the mutation panel results using an AmpliTaqGold 360 kit (Applied Biosystems, Foster City, CA). Following purification with ExoSAP-IT (Affymetrix USB, Cleveland, OH), the primer sequences were as follows: CACAAGGCTGCCCAGGTC and CAATGGCAGGCGTCTGTCC as PCR primers and GCTGAAGATGAGGAGGGGTAC as a sequencing primer for the splice region variant of exon 10 in SMARCA4. Other primers included AGGAGGAAGGCTCCGAATCC and TTCCTCCTCACTGTCATCGTCAC as PCR primers and GAAGACTCCATCGTCTTGCAG as a sequencing primer for the variant of exon 34 in SMARCA4. A 2-year-old girl developed a progressive headache and unsteadiness. Computed tomography of the brain revealed a large, calcified mass lesion in the pineal region, as well as obstructive hydrocephalus (Fig. 1A). Magnetic resonance imaging (MRI) revealed minor enhancement in a part of the tumor and high intensity on diffusion-weighted imaging (Fig. 1B–F). There was no evidence of metastasis on cerebrospinal fluid cytology or spinal MRI. Partial tumor resection was achieved, and the postoperative course was uneventful. Pathologically, the tumor cells showed varying degrees of neuronal differentiation, ranging from undifferentiated embryonal cells to ganglion cells (Fig. 1G–I). No rhabdoid cells or multilayered rosettes were observed. The neoplastic neuropil was positive for synaptophysin (Fig. 1J), and neurofilament proteins. Tumor cells showed occasional nuclear immunoreactivity for NeuN but were completely negative for GFAP (Fig. 1K), Olig2, S-100 protein, EMA, chromogranin A, and LIN28A. The MIB-1 index was as high as 28.7% in areas where undifferentiated embryonal cells congregated (Fig. 1L). By immunohistochemistry, both INI1 and BRG-1 (Fig. 1M), were present. Overall, according to the 2016 version of the WHO classification of CNS tumors, the diagnosis was CNS ganglioneuroblastoma at that time. After surgery, the patient received four courses of multi-agent chemotherapy consisting of cisplatin, vincristine, cyclophosphamide, etoposide, and intrathecal methotrexate according to the protocol for medulloblastoma and CNS-PNET in the Japan Pediatric Brain Tumor Consortium protocol; this was followed by local proton radiation therapy. There was a large calcified residual mass after the treatment; however, in the 5 years since diagnosis, the patient has been well and has not presented with evidence of recurrence or any neurological deficits associated with the tumor. (A) Sagittal noncontrast computed tomography scanning images. The images showed marked calcification in the tumors. (B–F) Axial view of T1-weighted images, T2WI, and diffusion weighted imaging of magnetic resonance. Axial and sagittal contrast-enhanced T1-weighted MR imaging showing minor enhancement of the tumor. The pathological findings indicate CNS ganglioneuroblastoma. Sheets of primitive embryonal cells and dispersed neurocytic and ganglion cells are embedded in the fibrillary matrix (G–I). The neoplastic neuropil and ganglion cells were positive for synaptophysin (J). Immunostaining for GFAP showed that reactive astrocytes were positive but tumor cells were negative (K). The MIB-1 immunolabeling index was approximately 25% in a sheet of undifferentiated embryonal cells (L). The tumor cells show diffuse nuclear immunoreactivity for BRG1 (M). Chromograms of a detected mutation (N) at the splice region of exon 10 in SMARCA4 and (O) one base deletion at exon 34 in SMARCA4. (P) t-distributed stochastic neighbor embedding (t-SNE) plotting of the methylation data of the case along with reference data. Mutation analysis detected a mutation in the splicing region of exon 10 (c.1761 + 1 G>C) and a one-base deletion in exon 34 (c.4777 delG) of SMARCA4 (Fig. 1N, O). The former mutation is described as “pathogenic” in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (https://cancer.sanger.ac.uk/cosmic/) and is not described in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/). The latter alteration is not described in ClinVar or COSMIC; however, it is indicated that this mutation leads to a change in the amino acid from valine (GTG) to a stop codon (TGA) at the third codon (p.Val1593Serfs*3). No alteration was observed in the dbSNP (https://www.ncbi.nlm.nih.gov/snp/) and SNP databases of the Japanese “jMorp” (https://www.megabank.tohoku.ac.jp/researchers/genome) population within the Tohoku Medical Megabank Organization (ToMMo). We subsequently performed DNA methylation analysis and t-SNE plotting of methylation data, which demonstrated that the case was not a CNS neuroblastoma with FOXR2 activation but clustered with AT/RT pattern (Fig. 1P). The methylation data were entered into the “methylation classifier” (v12.5) from the German cancer center and was classified as a methylation class “atypical teratoid/rhabdoid tumor, SHH activated” with a highly calibrated score of 0.93. Collectively, the case had pathological features of a CNS ganglioneuroblastoma but presented the DNA methylation signatures of AT/RT and SMARCA4 mutations. CNS ganglioneuroblastoma was previously considered to be a subtype of embryonal tumor in the CNS (1). The tumor was pathologically characterized by poorly differentiated neuroepithelial cells and groups of neurocytic and ganglion cells. Recently, CNS embryonal tumors have been extensively subdivided into several tumor entities based on the presence of distinct molecular profiles, including embryonal tumors with multilayered rosettes harboring C19MC amplifications (2). In this molecular-based diagnostic era, CNS ganglioneuroblastoma was removed from the recent version of the WHO classification, likely owing to the lack of specific molecular alteration or methylation profiling (2). CNS neuroblastoma with FOXR2 activation, which shows a pathological appearance similar to CNS ganglioneuroblastoma along with distinct methylation profiles and high FOXR2 expression levels, has been defined as one of the novel subgroups of embryonal tumors in the current version of the WHO classification (2). Thus, some tumors with CNS ganglioneuroblastoma pathological features may be classified as this tumor type. Following the molecular characterization of our case, it could be that CNS ganglioneuroblastomas may be molecularly heterogeneous and require further analyses to unveil relevant background genetic or epigenetic alterations. AT/RT has been defined as a CNS malignancy presenting with bi-allelic inactivation of SMARCB1 or SMARCA4 (7). Pathologically, these tumor specimens do not always demonstrate consistent features. There are various histological findings associated with these tumors, including primitive neuroectodermal, mesenchymal, and epithelial features. Notably, rhabdoid cells, one of the diagnostic hallmarks from a morphological standpoint, are not observed in all AT/RT cases (7). Regarding immunohistochemical staining, INI-1 is quite reliable for SMARCB1 mutant cases, although BRG-1 IHC may not lose the staining in some cases harboring SMARCA4 mutations. Similar to our results, multiple cases retained BRG-1 staining in the largest series of SMARCA4-mutated AT/RT cases (6). Interestingly, Nakano et al (8) also reported an infantile case of malignant brain tumor presenting pathologically as a yolk sac tumor with an SMARCA4 mutation and the methylation profiles of AT/RT; however, BRG-1 IHC was retained. Our case reminds us of the diagnostic limitation of the sole use of BRG-1 IHC for tumors with SMARCA4 mutations. DNA methylation analysis has emerged as a diagnostic tool for CNS tumors and this is particularly useful considering that tumors such as AT/RT have distinct methylation signatures (7). Through this analysis, SMARCB1 mutant tumors can be further classified into three groups: AT/RT_SHH, AT/RT_TYR, and AT/RT_MYC. Regarding SMARCA4-mutant AT/RT, Holdhof et al (6) reported that most tumors with SMARCA4 mutations clustered together apart from SMARCB1 mutant tumors. However, in their report, a number of SMARCA4 mutated cases were plotted close to other tumors, as in our case, indicating that SMARCA4 mutant AT/RT cases are not always epigenetically consistent. Among CNS tumors harboring SMARCB1/SMARCA4 mutations there were several reports of tumors which have not been classifiable in the current classification of CNS tumors, including CNS low-grade diffusely infiltrative tumors from Nobusawa et al (9), and a glial papillary tumor of the spinal cord by Hasselblatt et al (10). Our case might also be another un-recognized tumor with the alteration, although further research is needed with a larger cohort to confirm it. This report details a case of an embryonal tumor with the morphological appearance of CNS ganglioneuroblastomas in addition to SMARCA4 mutations and the methylation profiling data of an AT/RT. This case also indicates that genetic and epigenetic molecular approaches may facilitate the elucidation of the clinical heterogeneity of CNS embryonal tumors. Supported by Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, Gold Ribbons Network of Japan, a grant from the Saitama Children’s Medical Center (2019-B4), Children’s Cancer Association in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GanglioneuroblastomaRhabdoid TumorCentral Nervous System NeoplasmsNeoplasms, Germ Cell and EmbryonalTeratomaBrain NeoplasmsHumansMethylationMutationSMARCB1 ProteinDNA HelicasesNuclear ProteinsTranscription Factors

Substanzen

SMARCB1 ProteinSMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Clinical Research, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Pathology, Public Tomioka General Hospital, Tomioka, Japan.
  • Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
  • Department of Brain Disease Translational Research, Juntendo University Faculty of Medicine, Tokyo, Japan.

ORCID-Profile: Kohei Fukuoka

Förderung

  • Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics, Gold Ribbons Network of Japan
  • Saitama Children’s Medical Center
  • Children’s Cancer Association in Japan

Zitieren

APA

Fukuoka, K., Nakazawa, A., Hirato, J., Nobusawa, S., Itabashi, T., Arakawa, Y., Mori, M., Matsushita, Y., Honda, S., Tanami, Y., Ichimura, K., Kurihara, J., & Koh, K. (2023). An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlad033

Vancouver

Fukuoka K, Nakazawa A, Hirato J, Nobusawa S, Itabashi T, Arakawa Y, et al. An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation. Journal of Neuropathology & Experimental Neurology. 2023. doi:10.1093/jnen/nlad033

BibTeX
@article{Fukuoka2023,
  author = {Fukuoka, Kohei and Nakazawa, Atsuko and Hirato, Junko and Nobusawa, Sumihito and Itabashi, Toshikazu and Arakawa, Yuki and Mori, Makiko and Matsushita, Yuko and Honda, Satoko and Tanami, Yutaka and Ichimura, Koichi and Kurihara, Jun and Koh, Katsuyoshi},
  title = {An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2023},
  doi = {10.1093/jnen/nlad033}
}
Kostenlos starten →